These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

533 related items for PubMed ID: 30883456

  • 1. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
    Vo AA, Aubert O, Haas M, Huang E, Zhang X, Choi J, Peng A, Najjar R, Sethi S, Ammerman N, Lim K, Jordan SC.
    Transplantation; 2019 Dec; 103(12):2666-2674. PubMed ID: 30883456
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J, Xue W, Qing X, Jing X, Hou J, Tian X, Guo Q, He X, Cai J.
    Clin Transpl; 2014 Dec; ():223-30. PubMed ID: 26281149
    [Abstract] [Full Text] [Related]

  • 4. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H, Han E, Choi AR, Ban TH, Chung BH, Yang CW, Choi YJ, Oh EJ.
    PLoS One; 2018 Dec; 13(11):e0207434. PubMed ID: 30427941
    [Abstract] [Full Text] [Related]

  • 5. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM, Patel SJ, Burns KM, Dilioglou S, Gaber LW, Knight RJ, Gaber AO, Land GA.
    Clin Transpl; 2011 Dec; ():351-8. PubMed ID: 22755430
    [Abstract] [Full Text] [Related]

  • 6. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
    Vo AA, Sinha A, Haas M, Choi J, Mirocha J, Kahwaji J, Peng A, Villicana R, Jordan SC.
    Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D, Qi G, Tang Q, Li L, Yang C, Lin M, Wu B, Xu M, Cai J, Zhu T, Rong R.
    Clin Transpl; 2014 Jul; ():215-21. PubMed ID: 26281148
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D, Bach C, Staudner C, Böger CA, Bergler T, Banas B, Spriewald BM.
    Nephrol Dial Transplant; 2017 Apr 01; 32(4):730-737. PubMed ID: 28339671
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The Impact of Donor-Specific Anti-Human Leukocyte Antigen (HLA) Antibody Rebound on the Risk of Antibody Mediated Rejection in Sensitized Kidney Transplant Recipients.
    Lee KW, Park JB, Cho CW, Lee N, Yoo H, Kim K, Park H, Kang ES, Huh W, Kim S.
    Ann Transplant; 2017 Mar 28; 22():166-176. PubMed ID: 28348361
    [Abstract] [Full Text] [Related]

  • 15. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
    Malheiro J, Tafulo S, Dias L, Martins S, Fonseca I, Beirão I, Castro-Henriques A, Cabrita A.
    Transpl Int; 2017 Apr 28; 30(4):347-359. PubMed ID: 27717025
    [Abstract] [Full Text] [Related]

  • 16. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
    Zhang Q, Hickey M, Drogalis-Kim D, Zheng Y, Gjertson D, Cadeiras M, Khuu T, Baas AS, Depasquale EC, Halnon NJ, Perens G, Alejos J, Cruz D, Ali N, Shemin R, Kwon M, Fishbein MC, Ardehali A, Deng M, Reed EF.
    Transplantation; 2018 Oct 28; 102(10):e431-e438. PubMed ID: 29916988
    [Abstract] [Full Text] [Related]

  • 17. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M, Carroll RP, Tsiopelas E, Clayton P, Coates PT.
    Hum Immunol; 2020 Jul 28; 81(7):323-329. PubMed ID: 32327243
    [Abstract] [Full Text] [Related]

  • 18. Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes.
    Parajuli S, Joachim E, Alagusundaramoorthy S, Blazel J, Aziz F, Garg N, Muth B, Mohamed M, Mandelbrot D, Zhong W, Djamali A.
    Transplantation; 2019 Aug 28; 103(8):1722-1729. PubMed ID: 30507740
    [Abstract] [Full Text] [Related]

  • 19. The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies.
    Parajuli S, Aziz F, Blazel J, Muth BL, Garg N, Mohamed M, Rice J, Mezrich JD, Hidalgo LG, Mandelbrot D.
    Transplantation; 2021 Jul 01; 105(7):1548-1555. PubMed ID: 32732618
    [Abstract] [Full Text] [Related]

  • 20. Safety and Efficacy of a Steroid Avoidance Immunosuppression Regimen in Renal Transplant Patients With De Novo or Preformed Donor-Specific Antibodies: A Single-Center Study.
    Schutt R, Case J, Kurian SM, Spierling Bagsic SR, Barrick BL, Toll AE, Zhang Q, Reed EF, Quigley MM, Schaffer R, Fisher JS, Rice JC, Marsh CL.
    Transplant Proc; 2021 Apr 01; 53(3):950-961. PubMed ID: 33293041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.